SARS-CoV-2 Induced Interleukin -18 Response among Presumptive Covid-19 Patients in Kano State, Nigeria
Study’s Novelty/Excerpt • This study evaluates Interleukin-18 (IL-18) as a potential biomarker for COVID-19 by comparing its serum levels in COVID-19-positive patients and healthy controls. • The research uniquely identifies significantly elevated IL-18 levels in COVID-19 patients, demonstrati...
Saved in:
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Umaru Musa Yar'adua University, Katsina, Nigeria
2024-06-01
|
| Series: | UMYU Journal of Microbiology Research |
| Subjects: | |
| Online Access: | https://ujmr.umyu.edu.ng/index.php/ujmr/article/view/598 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850270500911054848 |
|---|---|
| author | Sanusi, U. I. Suraka, B. Aliyu, M. Muhammad, H. Kabuga, A. I. Usman, U. Imam, M. U. Al-Mukhtar, Y. A. Abbas, M. A. Auwal, Z. Tijjani, A. Sharif A. A. |
| author_facet | Sanusi, U. I. Suraka, B. Aliyu, M. Muhammad, H. Kabuga, A. I. Usman, U. Imam, M. U. Al-Mukhtar, Y. A. Abbas, M. A. Auwal, Z. Tijjani, A. Sharif A. A. |
| author_sort | Sanusi, U. I. |
| collection | DOAJ |
| description | Study’s Novelty/Excerpt
• This study evaluates Interleukin-18 (IL-18) as a potential biomarker for COVID-19 by comparing its serum levels in COVID-19-positive patients and healthy controls.
• The research uniquely identifies significantly elevated IL-18 levels in COVID-19 patients, demonstrating a strong statistical association with the infection (t value 6.16, p <0.00010).
• These findings underscore the potential of IL-18 in the prognosis and clinical management of COVID-19, offering new insights into its role in the disease's pathophysiology and its utility as a biomarker.
Full Abstract
Coronaviruses have a history of causing severe outbreaks with life-threatening consequences, including Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and the recent coronavirus disease 2019 (COVID-19). COVID-19 first broke out in Wuhan (China) in December 2019). The disease was later declared a pandemic, and so far, more than 222 countries have been affected, with over 771 million confirmed cases and total deaths of over 7.05 million. Some immunological markers were reported elsewhere as directly related to COVID-19 pathophysiology and stand a chance to be considered biomarkers. Interleukin 18 (IL-18) is a proinflammatory cytokine and a member of the interleukin-1 family, produced by macrophages at the early stage of viral infections. However, aberrant IL-18 production can lead to severe pathological injury. Hence, there is a need to assess the feasibility of interleukin -18 as a biomarker for COVID-19. Forty-five individuals diagnosed with COVID-19 and 45 healthy controls screened using a COVID-19 antigen rapid test kit and confirmed by one-step real-time PCR were recruited for this study. Blood samples were collected from the patients and controls, and the samples were analyzed for IL-18 using the ELISA technique. This study revealed a higher level of IL-18 in COVID-19-positive patients (206.42 ± 13.2 pg/mL) compared to the control group (97.96 ± 14.4 pg/mL). Serum level IL-18 was statistically associated with COVID-19 infection (t value 6.16, p <0.00010). The study demonstrates the importance of IL-18 in the COVID-19 cohort, inferentially implying its potential in the prognosis and clinical management of COVID-19. |
| format | Article |
| id | doaj-art-7de7a535aa944cf7a3c88725ea121197 |
| institution | OA Journals |
| issn | 2616-0668 2814-1822 |
| language | English |
| publishDate | 2024-06-01 |
| publisher | Umaru Musa Yar'adua University, Katsina, Nigeria |
| record_format | Article |
| series | UMYU Journal of Microbiology Research |
| spelling | doaj-art-7de7a535aa944cf7a3c88725ea1211972025-08-20T01:52:38ZengUmaru Musa Yar'adua University, Katsina, NigeriaUMYU Journal of Microbiology Research2616-06682814-18222024-06-0125926610.47430/ujmr.2493.032598SARS-CoV-2 Induced Interleukin -18 Response among Presumptive Covid-19 Patients in Kano State, NigeriaSanusi, U. I.0Suraka, B.1Aliyu, M.2Muhammad, H.3Kabuga, A. I.4Usman, U.5Imam, M. U.6Al-Mukhtar, Y. A.7Abbas, M. A.8Auwal, Z.9Tijjani, A.10Sharif A. A.11Centre for Advanced Medical Research and Training, Usmanu Danfodiyo University Sokoto, Sokoto State-NigeriaDepartment of Microbiology and Biotechnology, Faculty of Science, Federal University Dutse, Jigawa State-NigeriaDepartment of Medical Microbiology and Parasitology, Faculty of Clinical Sciences, Bayero University Kano, Kano State-NigeriaDepartment of Internal Medicine, Faculty of Clinical Sciences, Bayero University Kano, Kano State-NigeriaDepartment of Medical Microbiology and Parasitology, Faculty of Clinical Sciences, Bayero University Kano, Kano State-NigeriaDepartment of Biology Science, Jigawa state College of Education Gumel, Jigawa State-NigeriaCentre for Advanced Medical Research and Training, Usmanu Danfodiyo University Sokoto, Sokoto State-NigeriaDepartment of Medical Microbiology and Parasitology, Faculty of Clinical Sciences, Bayero University Kano, Kano State-NigeriaDepartment of Community Medicine, Faculty of Clinical Science, Bayero University Kano, Kano State-NigeriaCentre for Advanced Medical Research and Training, Usmanu Danfodiyo University Sokoto, Sokoto State-NigeriaDepartment of Epidemiology and Disease Control, College of Health Sciences, Jigawa state Polytechnic Dutse, Jigawa State-NigeriaDepartment of Medical Microbiology and Parasitology, Faculty of Clinical Sciences, Bayero University Kano, Kano State-NigeriaStudy’s Novelty/Excerpt • This study evaluates Interleukin-18 (IL-18) as a potential biomarker for COVID-19 by comparing its serum levels in COVID-19-positive patients and healthy controls. • The research uniquely identifies significantly elevated IL-18 levels in COVID-19 patients, demonstrating a strong statistical association with the infection (t value 6.16, p <0.00010). • These findings underscore the potential of IL-18 in the prognosis and clinical management of COVID-19, offering new insights into its role in the disease's pathophysiology and its utility as a biomarker. Full Abstract Coronaviruses have a history of causing severe outbreaks with life-threatening consequences, including Severe Acute Respiratory Syndrome (SARS), Middle East Respiratory Syndrome (MERS), and the recent coronavirus disease 2019 (COVID-19). COVID-19 first broke out in Wuhan (China) in December 2019). The disease was later declared a pandemic, and so far, more than 222 countries have been affected, with over 771 million confirmed cases and total deaths of over 7.05 million. Some immunological markers were reported elsewhere as directly related to COVID-19 pathophysiology and stand a chance to be considered biomarkers. Interleukin 18 (IL-18) is a proinflammatory cytokine and a member of the interleukin-1 family, produced by macrophages at the early stage of viral infections. However, aberrant IL-18 production can lead to severe pathological injury. Hence, there is a need to assess the feasibility of interleukin -18 as a biomarker for COVID-19. Forty-five individuals diagnosed with COVID-19 and 45 healthy controls screened using a COVID-19 antigen rapid test kit and confirmed by one-step real-time PCR were recruited for this study. Blood samples were collected from the patients and controls, and the samples were analyzed for IL-18 using the ELISA technique. This study revealed a higher level of IL-18 in COVID-19-positive patients (206.42 ± 13.2 pg/mL) compared to the control group (97.96 ± 14.4 pg/mL). Serum level IL-18 was statistically associated with COVID-19 infection (t value 6.16, p <0.00010). The study demonstrates the importance of IL-18 in the COVID-19 cohort, inferentially implying its potential in the prognosis and clinical management of COVID-19.https://ujmr.umyu.edu.ng/index.php/ujmr/article/view/598biomarkercovid-19interleukin-18kanosars-cov-2 |
| spellingShingle | Sanusi, U. I. Suraka, B. Aliyu, M. Muhammad, H. Kabuga, A. I. Usman, U. Imam, M. U. Al-Mukhtar, Y. A. Abbas, M. A. Auwal, Z. Tijjani, A. Sharif A. A. SARS-CoV-2 Induced Interleukin -18 Response among Presumptive Covid-19 Patients in Kano State, Nigeria UMYU Journal of Microbiology Research biomarker covid-19 interleukin-18 kano sars-cov-2 |
| title | SARS-CoV-2 Induced Interleukin -18 Response among Presumptive Covid-19 Patients in Kano State, Nigeria |
| title_full | SARS-CoV-2 Induced Interleukin -18 Response among Presumptive Covid-19 Patients in Kano State, Nigeria |
| title_fullStr | SARS-CoV-2 Induced Interleukin -18 Response among Presumptive Covid-19 Patients in Kano State, Nigeria |
| title_full_unstemmed | SARS-CoV-2 Induced Interleukin -18 Response among Presumptive Covid-19 Patients in Kano State, Nigeria |
| title_short | SARS-CoV-2 Induced Interleukin -18 Response among Presumptive Covid-19 Patients in Kano State, Nigeria |
| title_sort | sars cov 2 induced interleukin 18 response among presumptive covid 19 patients in kano state nigeria |
| topic | biomarker covid-19 interleukin-18 kano sars-cov-2 |
| url | https://ujmr.umyu.edu.ng/index.php/ujmr/article/view/598 |
| work_keys_str_mv | AT sanusiui sarscov2inducedinterleukin18responseamongpresumptivecovid19patientsinkanostatenigeria AT surakab sarscov2inducedinterleukin18responseamongpresumptivecovid19patientsinkanostatenigeria AT aliyum sarscov2inducedinterleukin18responseamongpresumptivecovid19patientsinkanostatenigeria AT muhammadh sarscov2inducedinterleukin18responseamongpresumptivecovid19patientsinkanostatenigeria AT kabugaai sarscov2inducedinterleukin18responseamongpresumptivecovid19patientsinkanostatenigeria AT usmanu sarscov2inducedinterleukin18responseamongpresumptivecovid19patientsinkanostatenigeria AT imammu sarscov2inducedinterleukin18responseamongpresumptivecovid19patientsinkanostatenigeria AT almukhtarya sarscov2inducedinterleukin18responseamongpresumptivecovid19patientsinkanostatenigeria AT abbasma sarscov2inducedinterleukin18responseamongpresumptivecovid19patientsinkanostatenigeria AT auwalz sarscov2inducedinterleukin18responseamongpresumptivecovid19patientsinkanostatenigeria AT tijjania sarscov2inducedinterleukin18responseamongpresumptivecovid19patientsinkanostatenigeria AT sharifaa sarscov2inducedinterleukin18responseamongpresumptivecovid19patientsinkanostatenigeria |